FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the

DARMSTADT, Germany and NEW YORK, February 11, 2019 /PRNewswire/ -- Not intended for US, Canada and UK-based media Merck and Pfizer Inc. today announced that ... Lees verder

Bron:

ANP Pers support